Efficacy and safety of collagenase Clostridium histolyticum in Peyronie’s disease following a modified treatment protocol.

Collagenase Clostridium histolyticum (CCH) is the only approved treatment for conservative management of Peyronie’s disease (PD) that has demonstrated efficacy and safety in clinical trials. However, as the standard treatment protocol is time and resource consuming, we are introducing a new CCH treatment protocol with a more cost-effective profile.

X